Why the study?
Can endomyocardial biopsy be safely performed and used to guide anthracycline therapy in pediatric patients?
Can endomyocardial biopsy be safely performed and used to guide anthracycline therapy in pediatric patients?
Endomyocardial biopsy is feasible with a reasonable complication rate in children and may help guide anthracycline therapy to prevent cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Should not change practice based on case reports; leaves open the need for prospective validation in pediatric anthracycline monitoring.
Evaluation of the ultrastructure of material obtained by endomyocardial biopsy has been proposed as a means to evaluate patients for impending anthracycline cardiotoxicity. Eighteen biopsies obtained from 13 patients (age, 3-18 years) are reported. Twelve biopsy procedures were done to evaluate the cardiac status on reaching a cumulative dose of 400 mg/m2 and three patients had six subsequent biopsies after having received significantly more drug or receiving radiation therapy to the lungs or mediastinum. Scores were assigned to the tissue obtained and used to guide the decision to continue or stop anthracycline therapy. Three patients with abnormal cardiac studies at low cumulative doses, five of whom had received greater than 400 mg/m2 and three of whom had received considerably higher doses and thoracic irradiation were given more drug without incident. Two specimens were interpreted to indicate avoidance of further anthracycline and two patients were cautiously given more despite evidence of mild myocardial damage. These results indicate that endomyocardial biopsies can be performed on a pediatric population with a reasonable complication rate. Further studies should be undertaken to evaluate its usefulness as a means to predict and avoid anthracycline cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Pegelow et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: